Table 5 Logistic regression analysis on the three-gene predictive index for radiographic response of 150 patients with measurable disease, including patients represented by the published data set

From: Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

 

Radiographic response a

Time to progression

Overall survival

 

P-value

OR (95% CI)

P-valueb

HR (95% CI)

P-valuec

HR (95% CI)

Univariate

 Three-gene predictive indexd

0.039

2.001 (1.036–3.864)

0.020

1.304 (1.042–1.631)

0.030

1.288 (1.026–1.618)

Multivariate

 Three-gene predictive index

0.059

1.902 (0.976–3.704)

0.019

1.309 (1.045–1.641)

0.018

1.316 (1.048–1.654)

 Age ⩾70 years

0.914

1.069 (0.318–3.598)

0.791

1.119 (0.486–2.577)

0.113

1.600 (0.895–2.862)

 Poor performance status (ECOG PS 2 or 3)

0.336

0.513 (0.132–1.999)

0.026

2.192 (1.097–4.381)

0.048

1.921 (1.004–3.677)

  1. Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OR, odds ratio; WHO, World Health Organization
  2. aNo clinical benefit (progressive disease according to the WHO criteria; n=46) vs clinical benefit (partial response and stable disease; n=104).
  3. bResult of Cox regression analysis on the three-gene predictive index for the time to progression of 123 patients in the training and the first validation sets.
  4. cResult of Cox regression analysis on the three-gene predictive index for the overall survival of all of 163 study patients including published data set.
  5. dComputed based on weighted average of log intensities of the three genes (EGFR, FGFR2 and MYC) obtained using a proportional hazards survival regression on the first two principal components of the log signal intensities of those three genes.
Back to article page